4.7 Article

Effect of Smoking on Outcomes of Primary PCI in Patients With STEMI

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 75, 期 15, 页码 1743-1754

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2020.02.045

关键词

infarct size; percutaneous coronary intervention (PCI); smoking; ST-segment elevation myocardial infarction (STEMI)

资金

  1. Bayer
  2. Janssen
  3. HeartFlow
  4. National Heart, Lung, and Blood Institute
  5. Abiomed
  6. Chiesi
  7. Portola
  8. AstraZeneca
  9. U.S. Food and Drug Administration
  10. National Institutes of Health
  11. GlaxoSmithKline
  12. Medtronic
  13. Novartis
  14. Apple
  15. Boehringer Ingelheim
  16. Bristol-Myers Squibb/Pfizer
  17. Abbott Vascular
  18. Boston Scientific
  19. CSI
  20. CathWorks
  21. Siemens
  22. Philips
  23. ReCor Medical

向作者/读者索取更多资源

BACKGROUND Smoking is a well-established risk factor for ST-segment elevation myocardial infarction (STEMI); however, once STEMI occurs, smoking has been associated with favorable short-term outcomes, an observation termed the smoker's paradox. It has been postulated that smoking might exert protective effects that could reduce infarct size, a strong independent predictor of worse outcomes after STEMI. OBJECTIVES The purpose of this study was to determine the relationship among smoking, infarct size, microvascular obstruction (MVO), and adverse outcomes after STEMI. METHODS Individual patient-data were pooled from 10 randomized trials of patients with STEMI undergoing primary percutaneous coronary intervention. Infarct size was assessed at median 4 days by either cardiac magnetic resonance imaging or technetium-99m sestamibi single-photon emission computed tomography. Multivariable analysis was used to assess the relationship between smoking, infarct size, and the 1-year rates of death or heart failure (HF) hospitalization and reinfarction. RESULTS Among 2,564 patients with STEMI, 1,093 (42.6%) were recent smokers. Smokers were 10 years younger and had fewer comorbidities. Infarct size was similar in smokers and nonsmokers (adjusted difference: 0.0%; 95% confidence interval [CI]: -3.3% to 3.3%; p = 0.99). Nor was the extent of MVO different between smokers and nonsmokers. Smokers had lower crude 1-year rates of all-cause death (1.0% vs. 2.9%; p < 0.001) and death or HF hospitalization (3.3% vs. 5.1%; p = 0.009) with similar rates of reinfarction. After adjustment for age and other risk factors, smokers had a similar 1-year risk of death (adjusted hazard ratio [adjHR]: 0.92; 95% CI: 0.46 to 1.84) and higher risks of death or HF hospitalization (adjHR: 1.49; 95% CI: 1.09 to 2.02) as well as reinfarction (adjHR: 1.97; 95% CI: 1.17 to 3.33). CONCLUSIONS In the present large-scale individual patient-data pooled analysis, recent smoking was unrelated to infarct size or MVO, but was associated with a worse prognosis after primary PCI in STEMI. The smoker's paradox may be explained by the younger age and fewer cardiovascular risk factors in smokers compared with nonsmokers. (C) 2020 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据